AXQ Capital’s Abeona Therapeutics ABEO Stock Holding History

AXQ Capital’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-33,581	Closed	-$177K	–	976
2025 Q4	$177K	Buy	+33,581	New	+$169K	0.04%	591

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AXQ Capital's ABEO Position: Q1 2026 in Review

AXQ Capital sold out of Abeona Therapeutics (ABEO) in Q1 2026, closing a stake of 33,581 shares — an estimated $177K sold.

AXQ Capital first reported a position in ABEO in Q4 2025 and held it in 1 quarter. The position peaked at $177K in Q4 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

AXQ Capital reported no remaining Abeona Therapeutics position as of Q1 2026 after selling out during the quarter.
AXQ Capital sold 33,581 Abeona Therapeutics shares in Q1 2026, an estimated $177K.
AXQ Capital first reported a position in Abeona Therapeutics in Q4 2025 and held it in 1 quarter.
AXQ Capital's Abeona Therapeutics position peaked at $177K in Q4 2025.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.